Omalizumab may not inhibit mast cell and basophil activation in vitro

In March 2014, omalizumab, a monoclonal anti‐IgE antibody, was approved for the treatment of chronic spontaneous urticaria (CSU). The primary mode of action of omalizumab is considered to be the reduction in free IgE serum levels and the subsequent down‐regulation of FcεRI, the high affinity receptor for IgE, on mast cells and basophils. Recently, it has been suggested that most CSU patients have an autoimmune aetiology which may lead to chronic activation of mast cells and basophils.

[1]  M. Maurer,et al.  The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. , 2015, The Journal of allergy and clinical immunology.

[2]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[3]  M. Maurer,et al.  Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. , 2014, Journal of dermatological science.

[4]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[5]  M. Maurer,et al.  Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H1‐antihistamines , 2012, Experimental dermatology.

[6]  M. Vogel,et al.  Inhibition of ongoing allergic reactions using a novel anti‐IgE DARPin‐Fc fusion protein , 2011, Allergy.

[7]  P. Martus,et al.  IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria? , 2011, PloS one.

[8]  J. Douglass,et al.  Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient , 2009, Allergy.

[9]  C. Bindslev‐Jensen,et al.  Peanut cross‐reacting allergens in seeds and sprouts of a range of legumes , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  R. Katz,et al.  Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. , 2008, Allergy and asthma proceedings.

[11]  T. Zuberbier,et al.  Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. , 2007, The Journal of allergy and clinical immunology.

[12]  S. Saini,et al.  Basophil FcɛRI histamine release parallels expression of Src-homology 2–containing inositol phosphatases in chronic idiopathic urticaria , 2007 .

[13]  S. Saini,et al.  Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. , 2007, The Journal of allergy and clinical immunology.

[14]  T. Kawakami,et al.  Mast Cell Survival and Activation by IgE in the Absence of Antigen: A Consideration of the Biologic Mechanisms and Relevance1 , 2005, The Journal of Immunology.

[15]  C. Grattan,et al.  Validation of basophil histamine release against the autologous serum skin test and outcome of serum‐induced basophil histamine release studies in a large population of chronic urticaria patients , 2005, Allergy.

[16]  Toshiaki Kawakami,et al.  Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcεRI , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Grattan,et al.  Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  W. Fridman,et al.  Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. , 1995, The Journal of clinical investigation.